TABLE 3.
MIC distributions for antimicrobials against all CRE isolated from blood specimens in China during 2018–2019.
| MIC (mg/L) | No.a | Percentages of isolates by MIC | MIC50 | MIC90 | MIC range | |||||||||||
|
|
|
|||||||||||||||
| Antibiotic | 0.03 | 0.06 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | ||||
| CRE (n = 653) | ||||||||||||||||
| Tigecycline | 646 | 1.39 | 1.86 | 10.22 | 39.16 | 20.12 | 21.83 | 4.49 | 0.62 | 0.31 | 0 | 0 | 0 | 0.25 | 1 | 0.03–8 |
| Polymyxin B | 650 | 0 | 0 | 0 | 4.77 | 54.31 | 22.92 | 12.15 | 2.15 | 1.08 | 1.38 | 1.23 | 0 | 0.5 | 2 | 0.25–32 |
| Ceftazidime/avibactam | 445 | 0 | 0.22 | 0.22 | 0.67 | 2.02 | 4.72 | 9.66 | 26.74 | 30.79 | 1.8 | 22.02 | 1.12 | 8 | 16 | 0.06–32 |
MIC, minimum inhibitory concentration; CRE, carbapenem-resistant Enterobacterales; MIC50, 50% minimum inhibitory concentration; MIC90, 90% minimum inhibitory concentration. aNo., number of isolates in which antibiotic sensitivity was tested.